Emerging treatment options for MZL
Catherine Thieblemont, MD, PhD, Saint-Louis University Hospital, Paris, France, discusses the evolving treatment landscape of marginal zone lymphoma (MZL), commenting on the efficacy and tolerability of emerging agents such as BTK inhibitors, PI3-Kinase inhibitors, CAR-T therapy, and bispecific antibodies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Watch video Emerging treatment options for MZL online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 21 June 2022, don't forget to share it with your friends and acquaintances, it has been viewed on our site 598 once and liked it 19 people.